Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
Allogene’s Off-the-Shelf CAR T Shows Early Skin Score Gains in First Scleroderma Data
Allogene Therapeutics (NASDAQ: ALLO), a clinical-stage developer of off-the-shelf CAR T cell therapies, reported on November 9, 2026 the first clinical data from its Phase 1 RESOLUTION study of ALLO-329 in autoimmune disease. Of 10 patients with skin-predominant systemic sclerosis, also known as scleroderma, 8 achieved and maintained a skin score improvement of at least 5 points, and no patient in the study had a dose-limiting toxicity.
“We are seeing meaningful and durable clinical improvement in patients with scleroderma,” said CEO Zachary Roberts, M.D., Ph.D.
How ALLO-329 and the Study Work
ALLO-329 is an investigational allogeneic CAR T product, meaning Allogene makes it from donor cells rather than each patient’s own cells. It targets both CD19 on B cells and CD70 on T cells. It also uses Allogene’s Dagger technology, which is designed to boost the activity of donor cells and potentially reduce or remove the need for lymphodepletion, the chemotherapy patients usually receive before CAR T treatment.
According to the company, lymphodepletion may be a significant barrier to CAR T adoption in chronic autoimmune diseases. For that reason, the study tests three approaches: no lymphodepletion, cyclophosphamide alone, or fludarabine plus cyclophosphamide. As of the September 21 data cutoff, 18 patients had received a single dose and completed the 28-day safety period, including 12 with systemic sclerosis, 4 with myositis and 2 with lupus. The FDA granted ALLO-329 three Fast Track designations in April 2025, covering lupus, myositis and scleroderma.
Early Results in Scleroderma
Among the 10 patients with skin-predominant systemic sclerosis, improvements in the modified Rodnan skin score appeared as early as Day 14. Those gains showed up across all three dose levels and lymphodepletion approaches, including the arm with no lymphodepletion. In addition, 4 patients reached a total skin score below 10, and several saw reductions of 10 points or more.
Nine of the 10 patients also remained off background immunosuppressive therapy at the cutoff, with the longest treatment-free interval extending beyond 8 months. “Systemic sclerosis remains a disease with substantial unmet need,” said Vivek Nagaraja, M.D., FACR, of Mayo Clinic Arizona, the lead author of the data presented at the ACR Convergence meeting. The company describes these results as preliminary, and it reported efficacy only for the skin-predominant scleroderma group so far.
Safety Profile and Path to Phase 2
Across all 18 patients, there were no cases of immune effector cell-associated neurotoxicity, hemophagocytic syndrome or graft-versus-host disease, and no Grade 3 or higher cytokine release syndrome. Cytokine release syndrome occurred in 4 patients, all at Grade 1 or 2. Three patients had a Grade 3 or higher treatment-emergent adverse event, and one had prolonged Grade 3 or higher low blood counts. Notably, no patient in the cohorts without lymphodepletion had an adverse event above Grade 2.
“Our goal has always been to develop ALLO-329 with safety as the top priority,” Roberts said. Dose escalation continues across five planned levels, from 20 million to 320 million cells, to select a Phase 2 regimen, and the company plans its next data readout for 2027. To fund that work, Allogene held $388.9 million in cash, cash equivalents and investments as of September 30, 2026, which it expects to fund operations into 2029.
Strategic Investment Summary
- First Clinical Data: Allogene Therapeutics (NASDAQ: ALLO) reported that 8 of 10 skin-predominant scleroderma patients treated with ALLO-329 achieved and maintained a skin score improvement of at least 5 points.
- Off Immunosuppressants: 9 of the 10 patients remained off background immunosuppressive therapy at the data cutoff, with the longest treatment-free interval beyond 8 months.
- Clean Safety Signals: Across 18 patients, the study recorded no dose-limiting toxicities, no neurotoxicity, no graft-versus-host disease and no Grade 3 or higher cytokine release syndrome.
- Lighter Pretreatment: Skin score gains appeared even in the arm with no lymphodepletion, and no patient in those cohorts had an adverse event above Grade 2.
- Regulatory Support: ALLO-329 holds three FDA Fast Track designations covering lupus, myositis and scleroderma.
- Runway Into 2029: Allogene held $388.9 million in cash and investments as of September 30, 2026, with dose escalation continuing and the next ALLO-329 readout planned for 2027.
Find out more about the latest corporate developments and financial reports at the Allogene Therapeutics investor portal.
The post Allogene’s Off-the-Shelf CAR T Shows Early Skin Score Gains in First Scleroderma Data appeared first on PRISM MarketView.
COMTEX_1002580114/2927/2026-11-09T14:51:03